{"DataElement":{"publicId":"3953322","version":"1","preferredName":"Tumor Marker Post Initial First Course Treatment Outcome Determination Status","preferredDefinition":"Text term that represents the tumor marker measured and the result of each test used to determine the patient's outcome at the completion of initial first course treatment.","longName":"3953319v1.0:3953292v1.0","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"3953319","version":"1","preferredName":"Tumor Marker Post Initial First Course Treatment Outcome Determination","preferredDefinition":"A substance present in or produced by a tumor or by the host, that can be used for differentiating neoplastic from normal tissue based on measurements in body fluids, secretions, cells, and/or tissues. Markers are used in diagnosis, staging and prognosis of cancer, provide an estimation of tumor burden, and serve for monitoring effects of therapy, detecting recurrence, localization of tumors, and screening in general populations._Happening at a time subsequent to a reference time; later in time or order._Preceding all others in time or space or degree._Passage through time; duration; a systematic or/and orderly succession; a sequence, e.g. course of treatment; a mode of action or behavior; natural development, typical manner of proceeding._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._Passage through time; duration; a systematic or/and orderly succession; a sequence, e.g. course of treatment; a mode of action or behavior; natural development, typical manner of proceeding._A specific result or effect that can be measured. Examples of outcomes include decreased pain, reduced tumor size, and improvement of disease._Anything that contributes causally to a result.","longName":"2443094v1.0:3953324v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2443094","version":"1","preferredName":"Tumor Marker","preferredDefinition":"A substance sometimes found in an increased amount in the blood, other body fluids, or tissues and which may mean that a certain type of cancer is in the body. Examples of tumor markers include CA 125 (ovarian cancer), CA 15-3 (breast cancer), CEA (ovarian, lung, breast, pancreas, and gastrointestinal tract cancers), and PSA (prostate cancer). Also called biomarker.","longName":"C17220","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tumor Marker","conceptCode":"C17220","definition":"A substance present in or produced by a tumor or by the host, that can be used for differentiating neoplastic from normal tissue based on measurements in body fluids, secretions, cells, and/or tissues. Markers are used in diagnosis, staging and prognosis of cancer, provide an estimation of tumor burden, and serve for monitoring effects of therapy, detecting recurrence, localization of tumors, and screening in general populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0A400EF7-3DF6-3538-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-01-16","endDate":null,"createdBy":"PWEST","dateCreated":"2006-01-16","modifiedBy":"ONEDATA","dateModified":"2006-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3953324","version":"1","preferredName":"Post First Therapeutic Procedure Course Outcome Factor","preferredDefinition":"Happening at a time subsequent to a reference time; later in time or order.:Preceding all others in time or space or degree.:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.:A period of protocol-prescribed activity or intervention.:The result of an action.:Factor; anything that contributes causally to a result.","longName":"3953324v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Post","conceptCode":"C38008","definition":"Happening at a time subsequent to a reference time; later in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"First","conceptCode":"C25509","definition":"Preceding all others in time or space or degree.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Course","conceptCode":"C25379","definition":"Passage through time; duration; a systematic or/and orderly succession; a sequence, e.g. course of treatment; a mode of action or behavior; natural development, typical manner of proceeding.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Outcome","conceptCode":"C20200","definition":"The result of an action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Factor","conceptCode":"C25506","definition":"Anything that contributes causally to a result.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EB78BCAD-A9FE-C88B-E040-BB89AD4330B5","latestVersionIndicator":"Yes","beginDate":"2013-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-18","modifiedBy":"ONEDATA","dateModified":"2013-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2842596","version":"1","preferredName":"Outcome of Therapy","preferredDefinition":"The result of therapy for a given disease or condition in a patient or group of patients.","longName":"C18919 ","context":"NCIP","contextVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"63D982FA-DFBF-58C7-E040-BB89AD433E84","latestVersionIndicator":"Yes","beginDate":"2009-02-26","endDate":null,"createdBy":"CURTIST","dateCreated":"2009-02-26","modifiedBy":"CURTIST","dateModified":"2009-02-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EB78BCAD-A8DA-C88B-E040-BB89AD4330B5","latestVersionIndicator":"Yes","beginDate":"2013-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-18","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"Created for Testicular Enrollment form per request by T.Lichtenberg. mc 11/17/13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3953292","version":"1","preferredName":"Tumor Marker Outcome Status","preferredDefinition":"A condition or state at a particular time.","longName":"3953292v1.0","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Luteinizing Hormone (LH) - Normal","valueDescription":"Luteinizing Hormone Normal","ValueMeaning":{"publicId":"3953306","version":"1","preferredName":"Luteinizing Hormone Normal","longName":"3953306","preferredDefinition":"A hormone made in the pituitary gland. In females, it acts on the ovaries to make follicles release their eggs and to make hormones that get the uterus ready for a fertilized egg to be implanted. In males, it acts on the testes to cause cells to grow and make testosterone.: Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recombinant Luteinizing Hormone","conceptCode":"C612","definition":"Any recombinant form of the endogenously produced heterodimer glycoprotein luteinizing hormone (LH) normally made by the anterior pituitary gland, that can be used for the treatment of LH deficiency. Upon administration, recombinant LH mimics the biological activity of endogenous LH. In females, this triggers ovulation and the development of the corpus luteum. In males, LH stimulates Leydig cells to produce testosterone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Normal","conceptCode":"C14165","definition":"Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EB792A70-68FA-D83F-E040-BB89AD430C78","latestVersionIndicator":"Yes","beginDate":"2013-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EB792A70-6913-D83F-E040-BB89AD430C78","beginDate":"2013-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-18","modifiedBy":"ONEDATA","dateModified":"2013-11-18","deletedIndicator":"No"},{"value":"Luteinizing Hormone (LH) - Elevated","valueDescription":"Luteinizing Hormone Elevated","ValueMeaning":{"publicId":"3953307","version":"1","preferredName":"Luteinizing Hormone Elevated","longName":"3953307","preferredDefinition":"A hormone made in the pituitary gland. In females, it acts on the ovaries to make follicles release their eggs and to make hormones that get the uterus ready for a fertilized egg to be implanted. In males, it acts on the testes to cause cells to grow and make testosterone.: Elevated; raised or increased.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recombinant Luteinizing Hormone","conceptCode":"C612","definition":"Any recombinant form of the endogenously produced heterodimer glycoprotein luteinizing hormone (LH) normally made by the anterior pituitary gland, that can be used for the treatment of LH deficiency. Upon administration, recombinant LH mimics the biological activity of endogenous LH. In females, this triggers ovulation and the development of the corpus luteum. In males, LH stimulates Leydig cells to produce testosterone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Elevated","conceptCode":"C25493","definition":"Raised or increased above normal levels or limits.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EB792A70-6920-D83F-E040-BB89AD430C78","latestVersionIndicator":"Yes","beginDate":"2013-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EB792A70-6939-D83F-E040-BB89AD430C78","beginDate":"2013-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-18","modifiedBy":"ONEDATA","dateModified":"2013-11-18","deletedIndicator":"No"},{"value":"Alpha Fetaprotein (AFP) - Progressed","valueDescription":"Alpha-Fetoprotein Disease Progression","ValueMeaning":{"publicId":"3953308","version":"1","preferredName":"Alpha-Fetoprotein Disease Progression","longName":"3953308","preferredDefinition":"Alpha-fetoprotein. A protein normally produced by a developing fetus. AFP levels are usually undetectable in the blood of healthy nonpregnant adults. An elevated level of AFP suggests the presence of either a primary liver cancer or germ cell tumor.: The worsening of a disease over time","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alpha-Fetoprotein","conceptCode":"C16278","definition":"Alpha-fetoprotein (609 aa, ~69 kDa) is encoded by the human AFP gene. This protein plays a role in the binding to copper, nickel, bilirubin and fatty acids in the fetal circulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Progression","conceptCode":"C17747","definition":"A process that manifests as the worsening of a disease over time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EB792A70-6953-D83F-E040-BB89AD430C78","latestVersionIndicator":"Yes","beginDate":"2013-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EB792A70-696C-D83F-E040-BB89AD430C78","beginDate":"2013-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-18","modifiedBy":"ONEDATA","dateModified":"2013-11-18","deletedIndicator":"No"},{"value":"Testosterone - Progressed","valueDescription":"Testosterone Disease Progression","ValueMeaning":{"publicId":"3953293","version":"1","preferredName":"Testosterone Disease Progression","longName":"3953293","preferredDefinition":"(tes-TOS-ter-own) A hormone that promotes the development and maintenance of male sex characteristics.: The worsening of a disease over time","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Testosterone","conceptCode":"C2299","definition":"A hormone made mainly in the testes (part of the male reproductive system). It is needed to develop and maintain male sex characteristics, such as facial hair, deep voice, and muscle growth. Testosterone may also be made in the laboratory and is used to treat certain medical conditions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Progression","conceptCode":"C17747","definition":"A process that manifests as the worsening of a disease over time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EB78BCAD-A633-C88B-E040-BB89AD4330B5","latestVersionIndicator":"Yes","beginDate":"2013-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EB78BCAD-A64C-C88B-E040-BB89AD4330B5","beginDate":"2013-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-18","modifiedBy":"ONEDATA","dateModified":"2013-11-18","deletedIndicator":"No"},{"value":"Testosterone - Normal","valueDescription":"Testosterone Normal","ValueMeaning":{"publicId":"3953294","version":"1","preferredName":"Testosterone Normal","longName":"3953294","preferredDefinition":"(tes-TOS-ter-own) A hormone that promotes the development and maintenance of male sex characteristics.: Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Testosterone","conceptCode":"C2299","definition":"A hormone made mainly in the testes (part of the male reproductive system). It is needed to develop and maintain male sex characteristics, such as facial hair, deep voice, and muscle growth. Testosterone may also be made in the laboratory and is used to treat certain medical conditions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Normal","conceptCode":"C14165","definition":"Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EB78BCAD-A659-C88B-E040-BB89AD4330B5","latestVersionIndicator":"Yes","beginDate":"2013-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EB78BCAD-A672-C88B-E040-BB89AD4330B5","beginDate":"2013-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-18","modifiedBy":"ONEDATA","dateModified":"2013-11-18","deletedIndicator":"No"},{"value":"Testosterone - Elevated","valueDescription":"Testosterone Elevated","ValueMeaning":{"publicId":"3953295","version":"1","preferredName":"Testosterone Elevated","longName":"3953295","preferredDefinition":"(tes-TOS-ter-own) A hormone that promotes the development and maintenance of male sex characteristics.: Elevated; raised or increased.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Testosterone","conceptCode":"C2299","definition":"A hormone made mainly in the testes (part of the male reproductive system). It is needed to develop and maintain male sex characteristics, such as facial hair, deep voice, and muscle growth. Testosterone may also be made in the laboratory and is used to treat certain medical conditions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Elevated","conceptCode":"C25493","definition":"Raised or increased above normal levels or limits.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EB78BCAD-A67F-C88B-E040-BB89AD4330B5","latestVersionIndicator":"Yes","beginDate":"2013-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EB78BCAD-A698-C88B-E040-BB89AD4330B5","beginDate":"2013-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-18","modifiedBy":"ONEDATA","dateModified":"2013-11-18","deletedIndicator":"No"},{"value":"Luteinizing Hormone (LH) - Progressed","valueDescription":"Luteinizing Hormone Disease Progression","ValueMeaning":{"publicId":"3953297","version":"1","preferredName":"Luteinizing Hormone Disease Progression","longName":"3953297","preferredDefinition":"A hormone made in the pituitary gland. In females, it acts on the ovaries to make follicles release their eggs and to make hormones that get the uterus ready for a fertilized egg to be implanted. In males, it acts on the testes to cause cells to grow and make testosterone.: The worsening of a disease over time","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recombinant Luteinizing Hormone","conceptCode":"C612","definition":"Any recombinant form of the endogenously produced heterodimer glycoprotein luteinizing hormone (LH) normally made by the anterior pituitary gland, that can be used for the treatment of LH deficiency. Upon administration, recombinant LH mimics the biological activity of endogenous LH. In females, this triggers ovulation and the development of the corpus luteum. In males, LH stimulates Leydig cells to produce testosterone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Progression","conceptCode":"C17747","definition":"A process that manifests as the worsening of a disease over time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EB78BCAD-A6A6-C88B-E040-BB89AD4330B5","latestVersionIndicator":"Yes","beginDate":"2013-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EB78BCAD-A6BF-C88B-E040-BB89AD4330B5","beginDate":"2013-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-18","modifiedBy":"ONEDATA","dateModified":"2013-11-18","deletedIndicator":"No"},{"value":"Alpha Fetaprotein (AFP) - Normal","valueDescription":"Alpha-Fetoprotein Normal","ValueMeaning":{"publicId":"3953298","version":"1","preferredName":"Alpha-Fetoprotein Normal","longName":"3953298","preferredDefinition":"Alpha-fetoprotein. A protein normally produced by a developing fetus. AFP levels are usually undetectable in the blood of healthy nonpregnant adults. An elevated level of AFP suggests the presence of either a primary liver cancer or germ cell tumor.: Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alpha-Fetoprotein","conceptCode":"C16278","definition":"Alpha-fetoprotein (609 aa, ~69 kDa) is encoded by the human AFP gene. This protein plays a role in the binding to copper, nickel, bilirubin and fatty acids in the fetal circulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Normal","conceptCode":"C14165","definition":"Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EB78BCAD-A6D2-C88B-E040-BB89AD4330B5","latestVersionIndicator":"Yes","beginDate":"2013-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EB78BCAD-A6EB-C88B-E040-BB89AD4330B5","beginDate":"2013-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-18","modifiedBy":"ONEDATA","dateModified":"2013-11-18","deletedIndicator":"No"},{"value":"Alpha Fetaprotein (AFP) - Elevated","valueDescription":"Alpha-Fetoprotein Elevated","ValueMeaning":{"publicId":"3953299","version":"1","preferredName":"Alpha-Fetoprotein Elevated","longName":"3953299","preferredDefinition":"Alpha-fetoprotein. A protein normally produced by a developing fetus. AFP levels are usually undetectable in the blood of healthy nonpregnant adults. An elevated level of AFP suggests the presence of either a primary liver cancer or germ cell tumor.: Elevated; raised or increased.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alpha-Fetoprotein","conceptCode":"C16278","definition":"Alpha-fetoprotein (609 aa, ~69 kDa) is encoded by the human AFP gene. This protein plays a role in the binding to copper, nickel, bilirubin and fatty acids in the fetal circulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Elevated","conceptCode":"C25493","definition":"Raised or increased above normal levels or limits.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EB78BCAD-A6F8-C88B-E040-BB89AD4330B5","latestVersionIndicator":"Yes","beginDate":"2013-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EB78BCAD-A711-C88B-E040-BB89AD4330B5","beginDate":"2013-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-18","modifiedBy":"ONEDATA","dateModified":"2013-11-18","deletedIndicator":"No"},{"value":"Human Chorionic Gonadotropin (HCG) - Progressed","valueDescription":"Human Chorionic Gonadotropin Disease Progression","ValueMeaning":{"publicId":"3953300","version":"1","preferredName":"Human Chorionic Gonadotropin Disease Progression","longName":"3953300","preferredDefinition":"A sialoglycoprotein hormone secreted by the placenta and maintains the corpus luteum at the beginning of the gestation period.(NCI): The worsening of a disease over time","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Human Chorionic Gonadotropin","conceptCode":"C2275","definition":"A sialoglycoprotein hormone secreted by the placenta and maintains the corpus luteum at the beginning of the gestation period.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Progression","conceptCode":"C17747","definition":"A process that manifests as the worsening of a disease over time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EB78BCAD-A71E-C88B-E040-BB89AD4330B5","latestVersionIndicator":"Yes","beginDate":"2013-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EB78BCAD-A737-C88B-E040-BB89AD4330B5","beginDate":"2013-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-18","modifiedBy":"ONEDATA","dateModified":"2013-11-18","deletedIndicator":"No"},{"value":"Human Chorionic Gonadotropin (HCG) - Normal","valueDescription":"Human Chorionic Gonadotropin Normal","ValueMeaning":{"publicId":"3953301","version":"1","preferredName":"Human Chorionic Gonadotropin Normal","longName":"3953301","preferredDefinition":"A sialoglycoprotein hormone secreted by the placenta and maintains the corpus luteum at the beginning of the gestation period.(NCI): Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Human Chorionic Gonadotropin","conceptCode":"C2275","definition":"A sialoglycoprotein hormone secreted by the placenta and maintains the corpus luteum at the beginning of the gestation period.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Normal","conceptCode":"C14165","definition":"Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EB78BCAD-A744-C88B-E040-BB89AD4330B5","latestVersionIndicator":"Yes","beginDate":"2013-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EB78BCAD-A75D-C88B-E040-BB89AD4330B5","beginDate":"2013-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-18","modifiedBy":"ONEDATA","dateModified":"2013-11-18","deletedIndicator":"No"},{"value":"Human Chorionic Gonadotropin (HCG) - Elevated","valueDescription":"Human Chorionic Gonadotropin Elevated","ValueMeaning":{"publicId":"3953302","version":"1","preferredName":"Human Chorionic Gonadotropin Elevated","longName":"3953302","preferredDefinition":"A sialoglycoprotein hormone secreted by the placenta and maintains the corpus luteum at the beginning of the gestation period.(NCI): Elevated; raised or increased.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Human Chorionic Gonadotropin","conceptCode":"C2275","definition":"A sialoglycoprotein hormone secreted by the placenta and maintains the corpus luteum at the beginning of the gestation period.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Elevated","conceptCode":"C25493","definition":"Raised or increased above normal levels or limits.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EB78BCAD-A76A-C88B-E040-BB89AD4330B5","latestVersionIndicator":"Yes","beginDate":"2013-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EB78BCAD-A783-C88B-E040-BB89AD4330B5","beginDate":"2013-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-18","modifiedBy":"ONEDATA","dateModified":"2013-11-18","deletedIndicator":"No"},{"value":"Lactate Dehydrogenase (LDH) - Progressed","valueDescription":"Lactate Dehydrogenase Disease Progression","ValueMeaning":{"publicId":"3953303","version":"1","preferredName":"Lactate Dehydrogenase Disease Progression","longName":"3953303","preferredDefinition":"A family of homotetrameric cytoplasmic enzymes involved in the conversion of L-lactate and NAD to pyruvate and NADH in the final step of anaerobic glycolysis. In vertebrates, genes for three different subunits (LDH-A, LDH-B and LDH-C) exist.: The worsening of a disease over time","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lactate Dehydrogenase","conceptCode":"C25184","definition":"A family of homotetrameric cytoplasmic enzymes involved in the conversion of L-lactate and NAD to pyruvate and NADH in the final step of anaerobic glycolysis. In vertebrates, genes for three different subunits (LDH-A, LDH-B and LDH-C) exist.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Progression","conceptCode":"C17747","definition":"A process that manifests as the worsening of a disease over time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EB78BCAD-A790-C88B-E040-BB89AD4330B5","latestVersionIndicator":"Yes","beginDate":"2013-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EB78BCAD-A7A9-C88B-E040-BB89AD4330B5","beginDate":"2013-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-18","modifiedBy":"ONEDATA","dateModified":"2013-11-18","deletedIndicator":"No"},{"value":"Lactate Dehydrogenase (LDH) - Normal","valueDescription":"Lactate Dehydrogenase Normal","ValueMeaning":{"publicId":"3953304","version":"1","preferredName":"Lactate Dehydrogenase Normal","longName":"3953304","preferredDefinition":"A family of homotetrameric cytoplasmic enzymes involved in the conversion of L-lactate and NAD to pyruvate and NADH in the final step of anaerobic glycolysis. In vertebrates, genes for three different subunits (LDH-A, LDH-B and LDH-C) exist.: Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lactate Dehydrogenase","conceptCode":"C25184","definition":"A family of homotetrameric cytoplasmic enzymes involved in the conversion of L-lactate and NAD to pyruvate and NADH in the final step of anaerobic glycolysis. In vertebrates, genes for three different subunits (LDH-A, LDH-B and LDH-C) exist.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Normal","conceptCode":"C14165","definition":"Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EB78BCAD-A7B6-C88B-E040-BB89AD4330B5","latestVersionIndicator":"Yes","beginDate":"2013-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EB78BCAD-A7CF-C88B-E040-BB89AD4330B5","beginDate":"2013-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-18","modifiedBy":"ONEDATA","dateModified":"2013-11-18","deletedIndicator":"No"},{"value":"Lactate Dehydrogenase (LDH) - Elevated","valueDescription":"Lactate Dehydrogenase Elevated","ValueMeaning":{"publicId":"3953305","version":"1","preferredName":"Lactate Dehydrogenase Elevated","longName":"3953305","preferredDefinition":"A family of homotetrameric cytoplasmic enzymes involved in the conversion of L-lactate and NAD to pyruvate and NADH in the final step of anaerobic glycolysis. In vertebrates, genes for three different subunits (LDH-A, LDH-B and LDH-C) exist.: Elevated; raised or increased.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lactate Dehydrogenase","conceptCode":"C25184","definition":"A family of homotetrameric cytoplasmic enzymes involved in the conversion of L-lactate and NAD to pyruvate and NADH in the final step of anaerobic glycolysis. In vertebrates, genes for three different subunits (LDH-A, LDH-B and LDH-C) exist.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Elevated","conceptCode":"C25493","definition":"Raised or increased above normal levels or limits.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EB78BCAD-A7DC-C88B-E040-BB89AD4330B5","latestVersionIndicator":"Yes","beginDate":"2013-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EB78BCAD-A7F5-C88B-E040-BB89AD4330B5","beginDate":"2013-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-18","modifiedBy":"ONEDATA","dateModified":"2013-11-18","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2842596","version":"1","preferredName":"Outcome of Therapy","preferredDefinition":"The result of therapy for a given disease or condition in a patient or group of patients.","longName":"C18919 ","context":"NCIP","contextVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"63D982FA-DFBF-58C7-E040-BB89AD433E84","latestVersionIndicator":"Yes","beginDate":"2009-02-26","endDate":null,"createdBy":"CURTIST","dateCreated":"2009-02-26","modifiedBy":"CURTIST","dateModified":"2009-02-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2404650","version":"1","preferredName":"Status","preferredDefinition":"A condition or state at a particular time.","longName":"C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"005AD6E5-057F-6A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-09-09","modifiedBy":"ONEDATA","dateModified":"2005-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EB78BCAD-A61A-C88B-E040-BB89AD4330B5","latestVersionIndicator":"Yes","beginDate":"2013-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-18","modifiedBy":"COOPERM","dateModified":"2013-12-02","changeDescription":"Created for Testicular enrollment form per request by T.Lichtenberg. mc 11/17/13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2756809","version":"1","longName":"TCGA (The Cancer Genome Atlas)","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6044923","version":"1","longName":"Active CDEs as of March 2017","context":"NCIP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Molecular Marker(s) Used to D","type":"Preferred Question Text","description":"Molecular Marker(s) Used to Determine Outcome at the Completion of Initial First Course Treatment","url":null,"context":"NCIP"}],"origin":"TCGA:The Cancer Genome Atlas","workflowStatus":"RELEASED","registrationStatus":"Application","id":"EB78BCAD-A972-C88B-E040-BB89AD4330B5","latestVersionIndicator":"Yes","beginDate":"2013-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-18","modifiedBy":"TSESU","dateModified":"2018-07-16","changeDescription":"Created for Testicular Enrollment form per request by T.Lichtenberg. mc 11/17/13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}